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 The term “globalization” was popularized by Marshall McLuhan in  War and Peace 
in the Global Village . In the book, 
McLuhan described how the global 
media shaped current events 
surrounding the Vietnam War [1] 
and also predicted how modern 
information and communication 
technologies would accelerate world 
progress through trade and knowledge 
development. Globalization now refers 
to a broad range of issues regarding 
the movement of goods and services 
through trade liberalization, and 
the movement of people through 
migration. 
 Much has also been written on 
the global effects of environmental 
degradation, population growth, and 
economic disparities. In addition, the 
pace of scientiﬁ c development has 
accelerated, with both negative and 
positive implications for global health. 
Concerns for national health transcend 
borders, with a need for shared 
human security and an enhanced role 
for international cooperation and 
development [2]. These issues have 
signiﬁ cant bioethical implications, and 
thus a renewed academic focus on the 
ethical dimensions of public health is 
needed.
 Future developments in science 
and health policy also require a ﬁ rm 
grounding in bioethical principles. 
These core principles include 
beneﬁ cence; nonmaleﬁ cence (to do no 
harm); respect for persons and human 
dignity (autonomy); and attention to 
equity and social justice. According to 
the World Health Organization [3], 
global ethical approaches should (1) 
monitor and update ethical norms for 
research, as necessary; (2) anticipate 
ethical implications of advances in 
science and technology for health; (3) 
apply internationally accepted codes of 
ethics; (4) ensure that agreed standards 
guide future work on the human 
genome; and (5) ensure that quality in 
health systems and services is assessed 
and promoted.
 The Bioethical Implications 
of Globalization Project
 The Bioethical Implications of 
Globalization (BIG) Project is a 
42-month dialogue funded by the 
European Commission that involves a 
series of expert panel discussions on 
four speciﬁ c globalization and health 
subject areas: (1) mobility of people; 
(2) technological globalization; (3) 
liberalization of trade; and (4) new 
global health threats (bioterrorism). 
In addition, BIG includes a multiple-
round Delphi Process (Box 1) to solicit 
input on these issues from a broad, 
interdisciplinary audience.
 The project’s purpose is both to raise 
short-term, practical considerations 
about globalization and health and 
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 Box 1. The Delphi Method 
 Delphi is a group communication 
technique designed to obtain opinions 
from a panel of selected experts on 
speciﬁ c issues through the sending 
of questionnaires to be completed 
within a speciﬁ ed time. The experts are 
contacted individually and they do not 
know other group participants and their 
opinions—the aim is to submit the group 
participants to the same conditions. 
Participants do not meet personally, 
thereby avoiding undue inﬂ uence. The 
process foresees the following points:
 • Identiﬁ cation of the problem
 • Selection of the relevant questions
 • Preparation and delivery of the ﬁ rst 
questionnaire 
 • Analysis of the answers and 
elaboration of the ﬁ rst synthesis; 
preparation and delivery of a second 
questionnaire containing reformulated 
questions based on such elements as 
results from analysis of and comments 
upon the ﬁ rst questionnaire, illustrative 
of how other participants have 
answered previous questions
 • Analysis and synthesis of answers
 • Delivery of further questionnaires as 
required
 The process is repeated a number of 
times, until a convergence of all group 
members is obtained. The process 
ends with analysis of the answers and 
formulation of the ﬁ nal report.
 (Adapted from http://www.bigproject.
org/dephi.htm) 
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to provide a longer-term, strategic 
perspective on the four selected 
public health–related issues. The 
ﬁ nal conclusions will be presented 
to a high-level meeting of European 
Union (EU) policy makers in 2006; 
these conclusions may then inform 
future research directions and 
stimulate additional critical thinking 
about globalization and its bioethical 
implications for health policy. This 
article presents preliminary results 
from the BIG Project.
 Mobility of People and 
Consequences for Health Systems
 Mobility results from the increasing 
ease of domestic and international 
travel as well as from instantaneous 
access to information through 
the Internet and other electronic 
resources. Mobility may involve the 
pursuit of a better quality of life, 
development of markets for traded 
goods and services, return of resources 
to home countries, and improvement 
of professional and business networks. 
 However, migration may also affect 
psychological and physical health as a 
result of conﬂ ict, famine, poverty, and 
the insufﬁ cient cultural or economic 
integration of migrants within their 
new home society. It may contribute to 
the spread of infectious diseases across 
borders (Figure 1). The recent epidemic 
of SARS was a classic example of an 
infectious disease propagated through 
the movement of people across borders; 
it required attention from the original 
site to control migration (quarantine) 
as well as vigilance by secondary sites 
to protect their populations (Figure 
2) [4]. For these and other reasons, 
the International Organization for 
Migration is increasingly concerned 
with migratory patterns and their health 
consequences in a globalizing world 
(for an illustration of the emerging 
conﬂ ict of ideas, see http:⁄⁄www.iom.
int and http:⁄⁄www.noborder.org/
iom/index.php).
 Cross-border health commerce is 
related to mobility. In Europe, this 
commerce is likely to increase as 
the EU enlarges to include Eastern 
and Central European nations. Such 
commerce may include the movement 
of health providers from East to 
West as well as “medical tourism” in 
pursuit of less costly or more accessible 
high-quality health care. In addition, 
international trade in illegal health 
products and inconsistent regulatory 
and safety standards for exports may 
threaten public health, especially in 
unregulated pharmaceutical markets. 
 Ethical concerns may also result from 
the vast growth in international tourist 
travel. Such travel now accounts for a 
twelfth of world trade, supporting an 
economy the size of a middle-income 
country [5]. Tourism may provide 
substantial economic beneﬁ ts to many 
developing countries, and it may 
improve cultural understanding among 
travelers. However, these beneﬁ ts 
require an ethical concern for the 
environment and for persons employed 
in the tourist industry.
 The rights of nations to protect 
against infectious disease and unsafe 
medical practices, as well as the rights 
of human beings displaced by war, 
trafﬁ cking, and economic and cultural 
disruption, are critical concerns for 
health policy makers. Poverty and social 
disparities are key factors in the growth 
of global migration. Therefore, it is 
timely to consider whether mobility 
is a human right, and whether those 
who migrate have rights to health care 
in their new country. These questions 
should be considered by health policy 
makers within the ethical contexts of 
individual autonomy, social justice, 
nonmaleﬁ cence, and beneﬁ cence.
 Technological Globalization and 
Health: Information Technology 
and Genomics
 Technology drives globalization and in 
turn is driven by globalization. However, 
there is considerable ambiguity as to 
the value of technological globalization, 
especially for health in low-income 
countries. The “digital divide” may 
be important in improving health or 
income disparities as the electronic 
revolution provides scientists and health 
workers in both the developed and 
developing world with unprecedented 
access to information. Much could be 
done to reduce information inequities 
for the developing world through 
collective international action, but 
new global governance mechanisms 
may be needed to achieve this goal for 
information technology [6]. 
 Interestingly, the Internet is a 
structural necessity for ﬁ nancial and 
corporate globalization, but the same 
technology is used by nongovernmental 
organizations, political groups, 
and cultural movements to support 
grassroots social justice and human 
rights campaigns against these 
globalizing corporations. Neither 
side in this struggle would advocate 
limitations to the expansion of Internet 
technology, but both sides need to 
consider the bioethical implications of 
increased information access.
 On the other hand, the ethical issues 
surrounding genomics (with both 
environmental and human concerns) 
are quite ambiguous. While there may 
be signiﬁ cant beneﬁ ts to identifying 
genetically beneﬁ cial products or 
genetic determinants of disease, there 
are also concerns about altering natural 
environments and about collecting 
routine genetic information from 
general populations [7]. 
 For example, some experts assert 
that genetically modiﬁ ed (GM) crops 
will signiﬁ cantly increase crop yields 
without requiring any additional 
farmland, thus preserving valuable 
rain forests and animal habitats. 
Other genetic innovations can 
reduce reliance on pesticides and 
herbicides that may contribute to 
environmental degradation. However, 
poor farmers may not be helped by 
GM technology. Five multinational 
companies (Monsanto [Creve Coeur, 
Missouri, United States], AstraZeneca 
[London, United Kingdom], DuPont 
[Wilmington, Delaware, United 
States], Pioneer Hi-Bred [Johnston, 
Iowa, United States], and Novartis 
[Basel, Switzerland]) control most of 
the GM seed market [8]. By linking 
their chemicals to seeds via GM 
technologies, these corporations 
extend markets for their fertilizers, 
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 Figure 1.  International Travel May 
Contribute to the Spread of Infectious 
Diseases across Borders 
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herbicides, and pesticides. Farmers 
are not allowed to trade or save GM 
seed from one harvest to the next, and 
“terminator technology” (producing 
grains that are genetically modiﬁ ed so 
that they cannot be used to generate 
new crops) is under development. 
(See http:⁄⁄www.globalissues.org/
EnvIssues/GEFood/Terminator.asp for 
more information on this technology.) 
Thus, ethical considerations of 
distributive justice and beneﬁ cence 
must be considered in the debate about 
the global applicability of GM crops.
 For the pharmaceutical and health 
care industries, genetic testing could 
provide information about the shape 
of future markets and the possible 
tailoring of speciﬁ c pharmacotherapy 
to genomic susceptibility. For 
governments, genetic testing may 
provide predictive information on 
a population basis that could aid 
future health care planning. Genetic 
information might also be similarly 
used by the insurance industry, but the 
identiﬁ cation of genetically “high-risk” 
individuals would likely interfere with 
their autonomy, in that they may not 
be able to purchase health insurance. 
For example, the Apolipoprotein E test 
may indicate that an individual has two 
copies of one form (allele e4) of the 
gene that leads to Alzheimer disease 
[9]. Could this information be used 
by insurance companies or possible 
employers to deny insurability, despite 
no current adverse health effects? 
 In the post-genomic era there is 
potential to both reduce and increase 
health inequities, but much will 
depend on how ethical issues are 
addressed. If interventions to increase 
the life span for those with access to 
high quality health care must compete 
with expensive investments in genetic 
research on infectious diseases (which 
affect the poor most of all), health 
inequalities may be ampliﬁ ed between 
those with access and those without 
access to health care. If research 
participants or patients in low-income 
countries have unequal access to 
information, they may not be properly 
informed about genetic testing and the 
counseling needed if adverse genetic 
information is found. Population-based 
genomic research may characterize 
groups of people in such a way that 
encourages discrimination. Such 
research may also lead to disputes 
about ownership of genetic resources 
from participant populations. Health 
professionals must have a solid 
grounding in bioethical issues as 
they make clinical decisions based on 
genetic information. However, health 
policy makers and global governance 
structures must also be accountable 
for the potential adverse consequences 
such decisions might engender. 
 One may ask: will genomic science 
really help developing nations? To 
what extent can beneﬁ ts be shared? 
Will pharmaceutical and biotechnology 
companies invest in poor countries if 
they can make more money working on 
therapeutics for high-income countries? 
Thus, concern for the bioethical issues 
of social justice and beneﬁ cence arises. 
Genomics has the potential to be a global 
public good, but there is considerable 
uncertainty as to its bioethical 
justiﬁ cation in all cultures [10].
 Liberalization of Trade 
and its Effects on Health
 In general, globalization helps liberalize 
trade through removal of import 
restrictions and tariffs, through removal 
of restrictions on trade in services, and 
through linkage of trade sanctions to 
the protection of intellectual property 
rights. All these activities may have an 
impact on population health.
 Defenders of trade liberalization 
claim that this process is one of the 
most effective means of increasing a 
country’s wealth and, by extension, 
population health. Even if this were 
always true, there may be speciﬁ c 
policies that have particularly 
detrimental effects on health (such 
as opening markets to trade in 
manufactured tobacco products). 
Further, there may be an ethical 
argument based on social justice 
against some trade liberalization 
policies. If, for example, trade 
liberalization between rich and poor 
countries produces proportionally 
more wealth in rich countries 
compared with poor countries, this 
may suggest a socially unjust result 
of liberalization; poor countries’ 
economies may not grow as fast as rich 
countries’ economies in this situation.
 The relationship between wealth 
and health is actually somewhat 
controversial: the so-called Preston 
curves demonstrate a dramatic 
relationship between health and 
economic prosperity up to about a 
Purchasing Power Parity of US$3,000 
per capita per year [11]. However, 
there are cheap, cost-effective 
approaches to population health (such 
as vaccination, clean water, and sewage 
disposal) that may not be affected 
by the increase in Purchasing Power 
Parity. These approaches were relatively 
more important than economic 
development per se in early 20th-
century interventions in developed 
countries, and they are likely to be 
more important for inﬂ uencing health 
among developing country populations 
today than simple economic growth. 
On the other hand, high-intensity 
technological improvement rather 
than economic growth may be more 
important to health in rich countries 
compared with developing countries.
 The concern for intellectual 
property rights in trade has been an 
extraordinarily contentious issue in 
recent years. Newer drugs that are 
effective against diseases in resource-
poor but highly impacted countries, 
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 Figure 2.  Scanning Electron Micrograph 
Showing the “Rosettelike” Appearance 
of the Matured SARS-CoV (Coronavirus) 
Particles (Arrows)
 This scanning electron micrograph emphasizes 
the form and structure of the virus particle, 
or virion, made visible with negative 
staining (inset) under transmission electron 
microscopy. Short and stubby spikes are 
visible on the virus surface.
 (Photo: CDC/Mary Ng Mah Lee, National 
University of Singapore, Singapore) 
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such as antiretroviral drugs against 
HIV, have been prohibitively expensive 
in these countries, in part because 
of patent protections. With the 
Trade-Related Intellectual Property 
agreement, patent protection became 
linked to trade policy; if countries in 
need of cheaper essential drugs did 
not conform to patent rules, trade 
retaliation from exporting countries 
might ensue. However, restrictions 
on poor countries’ responses to 
legitimate public health emergencies 
may be unethical on the basis of 
distributive justice, nonmaleﬁ cence, 
and beneﬁ cence. Exceptions for 
public health emergencies (such as 
HIV/AIDS) under the Trade-Related 
Intellectual Property agreement include 
the right to compulsory licensing (local 
companies produce patented medicines 
in exchange for a royalty payment to 
the patent holder) or parallel importing 
(importing patented drugs sold more 
cheaply elsewhere) that will make 
essential medicines more available to 
highly impacted countries without fear 
of trade retaliation from the originating 
country [12]. 
 The General Agreement on Trade 
in Services is a relatively new treaty 
that covers trade in health services 
[13]. The agreement has been severely 
criticized by some, who claim that 
it increases privatization of health 
care services and undermines public 
health care systems. However, given its 
ambiguities, the actual impact of the 
agreement on the health sector will be 
largely determined by the way in which 
the agreement is further speciﬁ ed 
in multinational commitments [14]. 
Social justice, equity, beneﬁ cence, and 
nonmaleﬁ cence will all come into play 
in the implementation of this treaty.
 New Global Health Threats, 
Focusing on Bioterrorism
 Concerns for security against biological 
weapons have recently arisen among 
both poor and wealthy nations. Some, 
however, question the enormous 
sums now being spent to address the 
perceived threats due to bioterrorism 
even without strong evidence for actual 
threats. Even without such evidence, 
global bioethical principles at least 
suggest the need for a framework for 
consideration of distributive justice in 
this arena. 
 For example, should a nation with 
a limited supply of a vaccine against 
weaponized smallpox offer its stockpiles 
to a neighboring country that is under 
direct attack? This case is complicated 
by the fact that the infection could 
spread to its own territory. In the case 
of widespread biological attacks, which 
global governing agency, country, or 
other entity would be responsible for 
global resource allocation? Clearly, 
risks from bioweapons are trans-border, 
but resources may be unevenly and 
inequitably distributed, requiring a 
bioethically based policy determination 
on a global basis [15]. 
 A further concern with respect to 
biomedical research is the issue of 
dual-use technology development for 
health beneﬁ ts as well as for possible 
bioweapons. Governments must balance 
the secrecy necessary for security with 
the need for disclosure of information 
that is essential for research and 
development in health. It is very difﬁ cult 
to sequester new knowledge that might 
be applied to building biological 
weapons without simultaneously 
impeding research on defense against 
those bioweapons and on other 
beneﬁ cial biomedical advances. Most 
BIG Project scientists agree that 
the beneﬁ ts of releasing scientiﬁ c 
information in general outweigh the 
risk of its misuse. However, the scientiﬁ c 
community needs to consider whether 
new codes of conduct are necessary 
or whether existing governance is 
sufﬁ cient to support a bioethical 
approach to research on possible dual-
use technologies. 
 Conclusion
 Global bioethical challenges require 
careful theoretical deliberation 
and practical considerations for 
international health policies [16]. 
The BIG Project seeks to guide these 
processes in four selected areas of 
interest to the EU, so that the project 
results may be helpful to policy makers 
at local, national, and international 
levels. 
 The BIG Project has found that 
bioethical principles are important 
in considerations of migration, trade, 
information technology, genomics, 
and bioweapons threats. Globalization 
in these arenas is neither a right nor a 
wrong process, but it demands careful 
consideration of bioethical principles 
including social justice, beneﬁ cence, 
nonmaleﬁ cence, and individual 
autonomy. These concerns may not be 
immediately obvious to health policy 
makers, and thus the BIG Project results 
may help clarify the larger goals and 
purposes of bioethically based health 
policy development within the EU and 
elsewhere. More information about the 
BIG Project can be found at http:⁄⁄www.
bigproject.org/project.htm.  
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